Recently, DaVita Labs, the dialysis division of
DaVita HealthCare Partners Inc.
) and Myriad RBM entered into a strategic liaison. Myriad RBM is
a wholly owned subsidiary of a leading molecular diagnostic
The association of the two companies is aimed at performing a
protein biomarker discovery research. The objective is to develop
and introduce diagnostic tests into the market so that they can
be of help in treating dialysis patients.
ANIKA THERAPEUT (ANIK): Free Stock Analysis
BIOGEN IDEC INC (BIIB): Free Stock Analysis
DAVITA INC (DVA): Free Stock Analysis Report
MYRIAD GENETICS (MYGN): Free Stock Analysis
To read this article on Zacks.com click here.
To aid the research on renal disease, the collaboration will use
the proprietary biorepository of DaVita that collects, processes,
stores and distributes biospecimens.
Myriad will process the bio-repository specimens of DaVita to
measure over 300 important proteins through its Myriad RBM
DiscoveryMAP platform. DiscoveryMAP analyses protein biomarkers
associated with inflammatory, metabolic and renal diseases. This
works as a helpful means for proper diagnosis of dialysis
Myriad is expected to commence processing the specimens in fiscal
Towards improving the quality of care for dialysis patients,
Myriad conducts extensive research in kidney disease and
inflammatory markers. On the other hand, DaVita is responsible
for providing dialysis services to patients suffering from
chronic kidney failure and end stage renal disease. The prospects
of biorepositories, led Myriad to join hands with DaVita in order
to improve its research and development efforts towards improving
Through the use of blood-based protein biomarkers, novel
diagnostic tests are capable of enhancing the quality of life for
patients as well as reduction of the overall healthcare costs.
For this, the tests focus on predicting vascular access failure.
An improvement in the quality of care and waning healthcare costs
is expected to lead to a surge in the number of patients served
by both Myriad and DaVita. Thus we expect the collaboration to
augment the financials for both the companies going forward. The
long term sales growth for Myriad is projected at 10.24% whereas
that of DaVita is 9.24%.
Myriad currently carries a Zacks Rank #2 (Buy). Among others in
Anika Therapeutics Inc.
Biogen Idec Inc.
) carry a favorable Zacks Rank #1 (Strong Buy) and appear